Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2003 Sep 12:2:11.
doi: 10.1186/1475-2840-2-11.

Cardiovascular diabetology in the core of a novel interleukins classification: the bad, the good and the aloof

Affiliations

Cardiovascular diabetology in the core of a novel interleukins classification: the bad, the good and the aloof

Enrique Z Fisman et al. Cardiovasc Diabetol. .

Abstract

Background: The impressive correlation between cardiovascular disease and glucose metabolism alterations has raised the likelihood that atherosclerosis and type 2 diabetes may share common antecedents. Inflammation is emerging as a conceivable etiologic mechanism for both. Interleukins are regulatory proteins with ability to accelerate or inhibit inflammatory processes.

Presentation of the hypothesis: A novel interleukins classification is described, based on their role in diabetes and atherosclerosis, hypothesizing that each interleukin (IL) acts on both diseases in the same direction--regardless if harmful, favorable or neutral.

Testing the hypothesis: The 29 known interleukins were clustered into three groups: noxious (the "bad", 8 members), comprising IL-1, IL-2, IL-6, IL-7, IL-8, IL-15, IL-17 and IL-18; protective (the "good", 5 members), comprising IL-4, IL-10, IL-11, IL-12 and IL-13; and "aloof", comprising IL-5, IL-9, IL-14, IL-16 and IL-19 through IL-29 (15 members). Each group presented converging effects on both diseases. IL-3 was reluctant to clustering.

Implications: These observations imply that 1) favorable effects of a given IL on either diabetes or atherosclerosis predicts similar effects on the other; 2) equally, harmful IL effects on one disease can be extrapolated to the other; and 3) absence of influence of a given IL on one of these diseases forecasts lack of effects on the other. These facts further support the unifying etiologic theory of both ailments, emphasizing the importance of a cardiovascular diabetologic approach to interleukins for future research. Pharmacologic targeting of these cytokines might provide an effective means to simultaneously control both atherosclerosis and diabetes.

PubMed Disclaimer

Figures

Figure 1
Figure 1
A cardiovascular diabetologic approach to the 29 known interleukins. The noxious interleukins ("bad") are depicted as red triangles, the protective ("good") as green circles, and the aloof as yellow squares. Interleukin-3 is depicted as a half red-half green square due to its ambiguity: albeit "good" in terms of glucose metabolism, it was not clustered into this group due to its effects on the heart (see text: Curtail of the scope).

References

    1. Stern MP. Diabetes and cardiovascular disease. The "common soil" hypothesis. Diabetes. 1995;44:369–374. - PubMed
    1. Tenenbaum A, Fisman EZ, Motro M. Metabolic syndrome and type 2 diabetes mellitus: focus on peroxisome proliferator activated receptors (PPAR) Cardiovasc Diabetol. 2003;2:4. doi: 10.1186/1475-2840-2-4. - DOI - PMC - PubMed
    1. Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV, Mitch W, Smith SC, Jr, Sowers JR. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation. 1999;100:1134–1146. - PubMed
    1. Blake GJ, Ridker PM. Inflammatory bio-markers and cardiovascular risk prediction. J Intern Med. 2002;252:283–294. doi: 10.1046/j.1365-2796.2002.01019.x. - DOI - PubMed
    1. Alexander RW. Inflammation and coronary artery disease. New Engl J Med. 1994;331:468–469. doi: 10.1056/NEJM199408183310709. - DOI - PubMed